Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Avanir

This page shows the latest Avanir news and features for those working in and with pharma, biotech and healthcare.

Otsuka presses on with Alzheimer’s agitation drug

Otsuka presses on with Alzheimer’s agitation drug

The investigational therapy is a new formulation of the active ingredients in Otsuka/Avanir's already-marketed Nuedexta (deudextromethorphan hydrobromide/quinidine sulphate) product. ... Otsuka and Avanir are also studying AVP-786 in mid-stage trials as

Latest news

  • Avanir’s week goes from bad to worse with Alzheimer’s stumble Avanir’s week goes from bad to worse with Alzheimer’s stumble

    Otsuka’s Avanir unit has been dealt yet another setback after its second phase 3 trial of its new drug for agitation in Alzheimer’s disease missed the mark. ... Otsuka paid $3.5bn to  acquire Avanir in 2014 as part of a strategy to expand its

  • Otsuka’s Alzheimer’s agitation drug hits the mark Otsuka’s Alzheimer’s agitation drug hits the mark

    All three drug classes have side effect issues, including drowsiness. AVP-786 – developed by Otsuka subsidiary Avanir in collaboration with Concert Pharma – offers the promise of a new medicine that could ... bridge the treatment gap” in agitated

  • Otsuka expands CNS presence with Avanir purchase Otsuka expands CNS presence with Avanir purchase

    Deal for US biotech is valued at $3.5bn. Japan-based Otsuka Pharmaceutical has agreed to buy the California biotech Avanir for $3.5bn, expanding its business in diseases of the ... Avanir also has a promising pipeline, including the compound AVP-786,

  • Avanir to co-promote Merck's diabetes drugs in the US Avanir to co-promote Merck's diabetes drugs in the US

    Under the agreement, Avanir will promote these products to healthcare professionals working in long-term care institutional setting, such as care homes. ... Rohan Palekar, chief commercial officer at Avanir, confirmed Merck's ambitions in the area.

  • Genzyme appoints MS and rare diseases business leaders

    He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Quick links